about
A polyvalent influenza A DNA vaccine induces heterologous immunity and protects pigs against pandemic A(H1N1)pdm09 virus infection.Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.Investigation of Human Cancers for Retrovirus by Low-Stringency Target Enrichment and High-Throughput SequencingSubstitutions of short heterologous DNA segments of intragenomic or extragenomic origins produce clustered genomic polymorphisms.High genetic diversity of measles virus, World Health Organization European Region, 2005-2006.Full-length characterization of A1/D intersubtype recombinant genomes from a therapy-induced HIV type 1 controller during acute infection and his noncontrolling partner.Molecular surveillance of circulating dengue genotypes through European travelers.Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost.Inactivation of orthopoxvirus for diagnostic PCR analysis.[Sandfly virus meningitis in a Danish traveller returning from Tuscany].Cases of travel-acquired dengue fever in Denmark 2001-2009.Natural mannosylation of HIV-1 gp120 imposes no immunoregulatory effects in primary human plasmacytoid dendritic cells.Cutavirus in Cutaneous Malignant MelanomaSequence conservation of subdominant HLA-A2-binding CTL epitopes in HIV-1 clinical isolates and CD8+ T-lymphocyte cross-recognition may explain the immune reaction in infected individuals.Sequence analysis of HIV-1 isolates from Guinea-Bissau: selection of vaccine epitopes relevant in both West African and European countries.Characterization of near full-length genomes of HIV type 1 strains in Denmark: basis for a universal therapeutic vaccine.Identification of conserved subdominant HIV Type 1 CD8(+) T Cell epitopes restricted within common HLA Supertypes for therapeutic HIV Type 1 vaccines.Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1.Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes.Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau.Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection.Terminal Pleistocene Alaskan genome reveals first founding population of Native Americans.The benefit of molecular characterization during a measles upsurge in Denmark.Identification of cowpox infection in a 13-year-old Danish boy.Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.Hepatitis C infection and risk of malignant lymphoma.P18-05. Evidence of escape mutations in HLA-A02 epitopes in HIV-1-positive patients after dendritic cell-based therapeutic vaccination with CD8 epitopes.Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization.The prehistoric peopling of Southeast AsiaInduction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopesEarly human dispersals within the AmericasP18-02. Peptide pulsed dendritic cells allows for induction of polyfunctional CD4+ T cell responses and help CD8+ T cell targeting subdominant CTL epitopesDevelopment of standard operating procedures to obtain longitudinal vaginal specimens from nulliparous rabbits as part of HIV vaccine mucosal immunogenicity studiesThe population history of northeastern Siberia since the PleistoceneContaminating viral sequences in high-throughput sequencing viromics: a linkage study of 700 sequencing librariesHigh-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach
P50
Q30428353-8A7BB3C9-A4B3-48C1-9E57-D506FEA335B8Q34984724-71061291-674A-4609-B910-1682ABBEB36AQ35749247-F89BC5F8-029F-4148-834F-75B612B727C8Q36221168-B3DF4EEA-DAE9-4F51-8B79-11C7D67533D0Q37008864-FF34D377-6893-4EDF-BAF0-32E3223717D5Q38876497-02BCD300-4269-4F4B-9646-64FF23A7875FQ38975543-B5EAA411-C404-4784-BAD4-F425C4E89640Q39562214-8E32C968-948D-49CF-A9B6-82A3E85514D2Q40081923-FA6E3035-0395-4641-B64C-F904FB2F4F34Q40310226-861FC00B-147C-4937-8A62-14D7D84FB451Q40318869-CCFD1998-8B9D-4528-ABB7-F5752299D9CEQ42223825-5B4060A9-797D-4E96-916A-C171D24F43F2Q42320064-45C35E94-F545-4212-A273-A3663EEDBC0DQ43681799-419E2011-9EF9-43C1-B372-71DE502E2BDCQ44216622-D794ECA9-9AB6-4390-9C29-A4721D3413E4Q44585399-6F6E01AC-B3DF-448F-A784-FA3029F22CCCQ44952607-49A7F983-6ECF-4CA9-A9FC-3F40092E3E1DQ45411816-CC548051-E645-4B85-B16A-FA063BCB6CCAQ45722233-7123AD4C-B805-4337-9D1E-DA4278DABA78Q45838627-6646ACC7-5C29-4BAC-A66A-76E21772F371Q46009472-21D35200-AACF-432F-B937-AC60130C8717Q47072625-AC163BC5-A96F-4E1E-9EBF-7509D0426C05Q50545741-100D2EB1-81D2-4D11-9A26-8267D88A280AQ50546959-2B6C979D-FB65-4EFF-9EA3-C56499FF21BDQ52913049-6AA79213-601C-4798-BD7E-36D7B15A3FF4Q54546863-41CE4FAA-3B21-4E35-944F-60860DF2CABAQ55206412-41DD0B2D-10A8-415A-B5E6-BA836F659B44Q55646150-83219530-CD0E-4AD4-97C5-BECFD20AF517Q56594152-570E504A-B8B4-4C94-827C-E243CD370013Q57916541-0C8D629B-26F9-46D5-BA61-847D4C6246F6Q58590211-CC056D28-2330-4C99-96CE-D17B9009E978Q59219807-1A8B6486-C1D0-40D3-8966-6AA31B1F3675Q60227818-BC7CC9D3-5691-41B9-8C15-194A1CCB8286Q64438037-8FC762D5-7999-47FB-8415-1CE3E7D6E4C1Q91792288-51A3992C-28CD-4754-8013-4363CF35DBCFQ93117453-32CBF9C9-43F7-4541-A8BD-2E4D70BEDFAF
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lasse Vinner
@ast
Lasse Vinner
@en
Lasse Vinner
@es
Lasse Vinner
@nl
Lasse Vinner
@sl
type
label
Lasse Vinner
@ast
Lasse Vinner
@en
Lasse Vinner
@es
Lasse Vinner
@nl
Lasse Vinner
@sl
prefLabel
Lasse Vinner
@ast
Lasse Vinner
@en
Lasse Vinner
@es
Lasse Vinner
@nl
Lasse Vinner
@sl
P106
P21
P31
P496
0000-0002-3081-3702